Pacific GeneTech Limited specializes in the development and commercialization of next-generation vaccines and biologics, primarily targeting veterinary applications but with potential implications for human health. The company utilizes its proprietary Aegis technology platform, which enables the creation of broad-spectrum vaccines that provide cross-protection against various pathogens, including bacteria, viruses, and parasites. Aegis vaccines can be administered in both live and inactivated forms, and they are designed to be delivered orally or via injection, significantly enhancing their usability compared to traditional vaccines. This platform employs recombinant technology to insert specific genes into microbial vectors, allowing for the production of universal antigens that offer protection across multiple strains and species.

In addition to the Aegis platform, Pacific GeneTech employs the Hercules adjuvant delivery system, a modified Chitosan adjuvant that enhances immune responses, particularly for orally administered vaccines. Hercules promotes the production of secretory immunoglobulin A (sIgA) on mucous membranes, which helps inhibit pathogen invasion. This adjuvant is integral to the efficacy of the inactivated vaccines within the Aegis platform and has been licensed for use in various veterinary applications, including poultry and swine vaccines. The company is actively pursuing collaborations and out-licensing opportunities to expand the reach of its innovative vaccine technologies across different animal species and potentially into human health applications.

Hong Kong

Pacific GeneTech (PGT) develops and commercialises novel vaccine and adjuvant technologies focusing on unmet needs in both the veterinary and human market sectors.PGT’s core technology is a proprietary platform for low cost orally administered recombinant vaccines against bacterial, viral and parasitic diseases.PGT is located in Arkansas, U.S., Hong Kong and PEI, Canada.

Pacific GeneTech Limited

Company Details